Displaying drugs 12126 - 12150 of 12390 in total
Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine
Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated to the hepatitis B surface antigen . Virus-like particles (VLPs) are protein-based vaccines that stimulate high immune responses because of the VLPs’...
Investigational
Matched Description: … SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a ... Virus-like particles (VLPs) are protein-based vaccines that stimulate high immune responses because of …
TMP
Experimental
MCC
Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria. MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing...
Investigational
Matched Description: … of mycobacteria. ... The product is a sterile biological composition in a sub-micron suspension. ... Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain …
QR-333
QR-333 has been investigated as a treatment for diabetic peripheral neuropathy. QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder that can lead to numbness, skin ulcers, constant pain...
Investigational
Matched Description: … to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder that ... QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed ... QR-333 has been investigated as a treatment for diabetic peripheral neuropathy. …
CLX-0921
CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma. It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to...
Investigational
Matched Description: … CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. ... CLX-0921 is a solid. ... It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity …
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group. It targets the protein serine/threonine-protein kinase B-raf.
Experimental
Matched Description: … These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl ... (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. …
Dexchlorpheniramine
Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine...
Experimental
Investigational
Matched Description: … Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. ... The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug …
BNT162c2 SARS-CoV-2 Vaccine
BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.[L15002, L15007]
BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728)...
Investigational
Matched Description: … BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a ... [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles …
N-Methylmesoporphyrin
N-methylmesoporphyrin is a solid. This compound belongs to the porphyrins. These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions by four methine groups to form a macrocyclic structure. This medication is known to target ferrochelatase.
Experimental
Matched Description: … These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions ... by four methine groups to form a macrocyclic structure. ... N-methylmesoporphyrin is a solid. This compound belongs to the porphyrins. …
INGN 225
INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53. INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer.
Investigational
Matched Description: … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector …
2'-C-methylcytidine
A nucleoside analog with anti-hepatitis C virus (HCV) activity. Upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus viral replication.
Experimental
Matched Description: … A nucleoside analog with anti-hepatitis C virus (HCV) activity. ... This blocks viral production of HCV RNA and thus viral replication. …
CYC116
CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers.
Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which...
Investigational
Matched Description: … mechanism consistent with inhibition of Aurora kinase. ... CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis ... third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a …
OPC-28326
At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being...
Investigational
Matched Description: … It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome …
NOX-100
NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple...
Investigational
Matched Description: … NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind ... and inactivate NO, a simple gas molecule that is a key biological messenger in the body. ... agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a …
Deanol
Deanol is commonly referred to as 2-(dimethylamino)ethanol, dimethylaminoethanol (DMAE) or dimethylethanolamine (DMEA). It holds tertiary amine and primary alcohol groups as functional groups. Deanol has been used in the treatment of attention deficit-hyperactivity disorder (ADHD), Alzheimer's disease, autism, and tardive dyskinesia. It has been also used as an ingredient in...
Experimental
Matched Description: … Deanol has been used in the treatment of attention deficit-hyperactivity disorder (ADHD), Alzheimer's …
Coronavirus-Like Particle COVID-19 Vaccine
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the...
Investigational
Matched Description: … A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity ... vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of ... of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged 18-55 …
Zebularine
A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Experimental
Matched Description: … It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as ... A chemically stable, cytidine analog that displays anti-tumor properties. …
IR208
IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation.
It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients. IR208 is currently undergoing Phase II
studies in a 200-patient trial.
Investigational
Matched Description: … It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients ... IR208 is currently undergoing Phase II
studies in a 200-patient trial. ... IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation. …
IMC-1C11
IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Investigational
Matched Description: … IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma. ... It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction …
Displaying drugs 12126 - 12150 of 12390 in total